- Home
- LAB vs VNDA Comparison
LAB vs VNDA Comparison
Compare LAB & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LAB | VNDA |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.4M | 474.0M |
| IPO Year | 2008 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LAB | VNDA |
|---|---|---|
| Price | $0.96 | $8.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $1.35 | ★ $14.90 |
| AVG Volume (30 Days) | 2.4M | ★ 3.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.54 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $101,937,000.00 | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.50 |
| Revenue Next Year | $2.63 | $38.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $0.92 | $3.81 |
| 52 Week High | $1.72 | $9.91 |
Technical Indicators
Market Signals| Indicator | LAB | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 31.69 | 53.74 |
| Support Level | $0.92 | $7.39 |
| Resistance Level | $1.41 | $9.53 |
| Average True Range (ATR) | 0.06 | 0.51 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 14.97 | 39.14 |
Price Performance
Historical ComparisonAbout LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.